Arca Biopharma Inc (ABIO)

HEALTH CARE: PHARMACEUTICALS
SIC: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES

10170 CHURCH RANCH WAY WESTMINSTER, CO 80021

ARCA biopharma is dedicated to developing genetically targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. ARCA's lead product candidate, GencaroTM(bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for the potential treatment of atrial fibrillation in heart failure patients. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically targeted AF prevention treatment. The U.S. FDA has granted the Gencaro development program Fast Track designation and a Special Protocol Assessment (SPA) agreement for a single Phase 3 clinical trial. ARCA is also developing AB171, a thiol-substituted isosorbide mononitrate, as a potential genetically targeted treatment for heart failure and peripheral arterial disease.

Data as of 2021-08-02 08:04:09 -0400
Market Cap45.536 Million Shares Outstanding14.41 Million Avg 30-day Volume650.604 Thousand
P/E Ratio Dividend Yield EPS
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE Enterprise Value
Total Cash Current Debt Gross Profit
BETA0.69313 52-week High/Low6.99 / 2.72 Next Earnings Date2021-08-05 Price to Cash FLow (P/CF) -9999999.0
Data provided by IEX Cloud
View SEC Filings from ABIO instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 0 0 (0.0%) 0 (0.0%)
Funds Holding: 18 21 -14.29% 5 (0.29%) 5 (0.29%) 0.0%
13F shares: 876.824 Thousand 821.335 Thousand 6.76% 249.631 Thousand 295.098 Thousand -15.41%
% Ownership 6.0848 8.8112 -30.94% 1.7323 3.1658 -45.28%
New Positions: 4 10 -60.0% 2 4 -50.0%
Increased Positions 6 4 50.0% 3 1 200.0%
Closed Positions 7 5 40.0% 2 3 -33.33%
Reduced Positions 3
Total Calls 69.747 Thousand 59 118115.25% 41.4 Thousand
Total Puts 33.847 Thousand 12.5 Thousand 170.78% 11.2 Thousand
PUT/CALL Ratio 0.49 211.86 -99.77% 0.27 -99.87%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Arca Biopharma Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding ABIO (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ABIO BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

CONWAY ROBERT E

  • Director
  • CHAIRMAN OF THE BOARD
 50,000 2021-05-13 7

DEKKER C. JEFFREY CHIEF FINANCIAL OFFICER

  • Officer
 0 2021-05-10 1

GRAIS LINDA

  • Director
 0 2021-01-12 1

WOOSLEY RAYMOND L.

  • Director
 0 2021-01-12 1

MITCHELL DANIEL J

  • Director
 611 2021-01-12 1

HOVE ANDERS D

  • Director
 0 2021-01-12 1

BRISTOW MICHAEL R PRES. & CHIEF EXECUTIVE OFFIC

  • Officer
  • Director
 4,808 2020-12-21 1

OZEROFF CHRISTOPHER DAVID S.V.P., GENERAL COUNSEL

  • Officer
 970 2020-12-21 1

SELBY BRIAN L. VP, FINANCE

  • Officer
 0 2020-12-21 1

KEUER THOMAS A CHIEF OPERATING OFFICER

  • Officer
 730 2020-12-21 1

GROWTH EQUITY OPPORTUNITIES IV, LLC

NEW ENTERPRISE ASSOCIATES 15, L.P.

NEA PARTNERS 15, L.P.

NEA 15 GP, LLC

  • 10% Owner
 No longer subject to file 2018-02-26 0

SONSINI PETER W.

  • 10% Owner
 No longer subject to file 2018-02-26 0

SAKODA JON

  • 10% Owner
 No longer subject to file 2018-02-26 0

MAKOWER JOSHUA

  • 10% Owner
 No longer subject to file 2018-02-26 0

VISWANATHAN RAVI

  • 10% Owner
 No longer subject to file 2018-02-26 0

SANDELL SCOTT D

  • 10% Owner
 No longer subject to file 2018-02-26 0

FLORENCE ANTHONY A. JR.

  • 10% Owner
 No longer subject to file 2018-02-26 0

MOTT DAVID M

  • 10% Owner
 No longer subject to file 2018-02-26 0

BASKETT FOREST

  • 10% Owner
 No longer subject to file 2018-02-26 0

BARRIS PETER J

  • 10% Owner
 No longer subject to file 2018-02-26 0

VENROCK HEALTHCARE CAPITAL PARTNERS LP

VHCP CO-INVESTMENT HOLDINGS, LLC

VHCP MANAGEMENT, LLC

VENROCK HEALTHCARE CAPITAL PARTNERS II, L.P.

VHCP CO-INVESTMENT HOLDINGS II, LLC

VHCP MANAGEMENT II, LLC

KOH BONG Y

SHAH NIMISH P

  • 10% Owner
 No longer subject to file 2018-02-26 0

VENROCK HEALTHCARE CAPITAL PARTNERS LP

VENROCK HEALTHCARE CAPITAL PARTNERS II, L.P.

VHCP CO-INVESTMENT HOLDINGS, LLC

VHCP CO-INVESTMENT HOLDINGS II, LLC

KOH BONG Y

HOVE ANDERS D

VHCP MANAGEMENT, LLC

VHCP MANAGEMENT II, LLC

  • 10% Owner
 10,789,324 2015-06-16 0

WELLER HARRY R

  • 10% Owner
 10,221,465 2015-06-16 0

KOLLURI KRISHNA KITTU

  • 10% Owner
 10,221,465 2015-06-16 0

MCCORMACK RILEY

  • 10% Owner
 No longer subject to file 2015-01-14 0

WHEELER PATRICK M CHIEF FINANCIAL OFFICER

  • Officer
 101,510 2014-09-18 0

ZABRISKIE JOHN L

  • Director
 0 2013-09-17 0

ATLAS VENTURE FUND VII L P

ATLAS VENTURE ASSOCIATES VII, L.P.

  • 10% Owner
 1,579,542 2012-10-25 0

FORMELA JEAN FRANCOIS

  • Director
  • 10% Owner
 1,579,542 2012-10-22 0

SOBEL BURTON E

  • Director
 0 2012-02-10 0

BREWER RICHARD B

  • Director
 0 2012-02-10 0

ATLAS VENTURE FUND VII L P

  • 10% Owner
 1,337,612 2010-03-29 0

PENDERGAST MARY K

  • Director
 0 2010-02-05 0

FREYTAG J WILLIAM

  • Director
 0 2010-02-05 0

LOVE TED W

  • Director
 0 2010-02-05 0

LOWE DAVID GEORGE

  • Director
 No longer subject to file 2009-07-17 0

FALBERG KATHRYN E CFO AND COO

  • Officer
 0 2009-06-25 0

SKYLINE VENTURE PARTNERS QUALIFIED PURCHASER FUND IV L P

  • FORMER 10% OWNER
 No longer subject to file 2009-06-11 0

BOULDER VENTURES IV ANNEX LP

BOULDER VENTURES IV LP

BV PARTNERS IV, L.L.C.

FIDLER JOSH E

JONES ANDREW E

LEFKOFF KYLE

MACKS LAWRENCE M

ROSHKO PETER

  • 10% Owner
 No longer subject to file 2009-04-06 0

ST LAURENT RANDALL EVP COMMERCIAL OPERATIONS

  • Officer
 0 2009-01-27 0

BENDEKGEY E LEE CFO AND TREASURER

  • Officer
 1,502 2008-12-31 0

GAVIN JAMES R III

  • Director
 0 2008-06-04 0

PERRY MARK L

  • Director
 0 2008-06-04 0

POPOVITS KIMBERLY J

  • Director
 0 2008-06-04 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
ARCA BIOPHARMA INC ABIO 2021-08-03 15:45:03 UTC -1.7358 1.7958 400000
ARCA BIOPHARMA INC ABIO 2021-08-03 15:15:03 UTC -1.7358 1.7958 400000
ARCA BIOPHARMA INC ABIO 2021-08-03 14:45:04 UTC -1.7358 1.7958 400000
ARCA BIOPHARMA INC ABIO 2021-08-03 14:15:03 UTC -1.7358 1.7958 400000
ARCA BIOPHARMA INC ABIO 2021-08-03 13:45:03 UTC -1.7358 1.7958 400000
ARCA BIOPHARMA INC ABIO 2021-08-03 13:15:03 UTC -1.7358 1.7958 400000
ARCA BIOPHARMA INC ABIO 2021-08-03 12:45:03 UTC -1.7358 1.7958 350000
ARCA BIOPHARMA INC ABIO 2021-08-02 22:15:03 UTC -1.7358 1.7958 300000
ARCA BIOPHARMA INC ABIO 2021-08-02 21:45:03 UTC -1.7358 1.7958 300000
ARCA BIOPHARMA INC ABIO 2021-08-02 21:15:03 UTC -1.7358 1.7958 300000
ARCA BIOPHARMA INC ABIO 2021-08-02 20:45:03 UTC -1.6347 1.6947 300000
ARCA BIOPHARMA INC ABIO 2021-08-02 20:15:03 UTC -1.6347 1.6947 300000
ARCA BIOPHARMA INC ABIO 2021-08-02 19:45:03 UTC -1.6347 1.6947 300000
ARCA BIOPHARMA INC ABIO 2021-08-02 19:15:03 UTC -1.6347 1.6947 300000
ARCA BIOPHARMA INC ABIO 2021-08-02 18:45:03 UTC -1.6034 1.6634 300000
ARCA BIOPHARMA INC ABIO 2021-08-02 18:15:03 UTC -1.6034 1.6634 300000
ARCA BIOPHARMA INC ABIO 2021-08-02 17:45:03 UTC -1.6034 1.6634 300000
ARCA BIOPHARMA INC ABIO 2021-08-02 17:15:03 UTC -1.6034 1.6634 400000
ARCA BIOPHARMA INC ABIO 2021-08-02 16:45:03 UTC -1.6296 1.7096 400000
ARCA BIOPHARMA INC ABIO 2021-08-02 16:15:03 UTC -1.6296 1.7096 300000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments